Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells
- PMID: 15265880
- DOI: 10.4049/jimmunol.173.3.1526
Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells
Abstract
It has been known for some time that functional properties of dendritic cells (DC), and in particular their ability to process and present Ags to T cells, can be modulated by cytokine-induced maturation and by interactions with tumor cells. However, the molecular basis for these functional changes is unknown. We have investigated whether changes in expression of Ag-processing machinery (APM) components in DC are associated with alterations in their ability to present tumor-derived Ags to T cells. Using a panel of mAbs specific for individual APM components and a quantitative flow cytometry-based method, the level of APM components was measured in DC generated from peripheral blood monocytes of 12 normal donors and of 8 patients with cancer. Immature DC had significantly lower (p < 0.01) expression of MB1, LMP-7, LMP-10, TAP-1, and tapasin than mature DC. However, maturation in the presence of a cytokine mixture up-regulated expression of these components in DC obtained from normal donors and patients with cancer. Immature DC incubated with tumor cells had significantly lower (p < 0.001) expression of MB1, LMP-2, LMP-7, LMP-10, and endoplasmic reticulum p75 than controls. These changes were associated with a decreased ability of DC to present tumor-derived Ags to T cells, as measured in ELISPOT assays and with apoptosis of T cells in DC-T cell cultures. Thus, tumor cells have a significant suppressive effect on DC; however, ex vivo maturation of DC derived from patients with cancer in a polarizing cytokine mix restores normal expression of APM components and Ag-processing capabilities.
Similar articles
-
Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation.Int Immunol. 2001 Dec;13(12):1515-23. doi: 10.1093/intimm/13.12.1515. Int Immunol. 2001. PMID: 11717192
-
Hepatocytes express abundant surface class I MHC and efficiently use transporter associated with antigen processing, tapasin, and low molecular weight polypeptide proteasome subunit components of antigen processing and presentation pathway.J Immunol. 2005 Jul 15;175(2):1047-55. doi: 10.4049/jimmunol.175.2.1047. J Immunol. 2005. PMID: 16002705
-
Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.J Immunother. 2009 Jun;32(5):465-73. doi: 10.1097/CJI.0b013e3181a1c24e. J Immunother. 2009. PMID: 19609238 Free PMC article.
-
Genes regulating MHC class I processing of antigen.Curr Opin Immunol. 1999 Feb;11(1):82-8. doi: 10.1016/s0952-7915(99)80015-6. Curr Opin Immunol. 1999. PMID: 10047538 Review.
-
Antigen-processing machinery breakdown and tumor growth.Immunol Today. 2000 Sep;21(9):455-64. doi: 10.1016/s0167-5699(00)01692-3. Immunol Today. 2000. PMID: 10953098 Review.
Cited by
-
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.J Immunol. 2009 Jul 1;183(1):137-44. doi: 10.4049/jimmunol.0900734. Epub 2009 Jun 17. J Immunol. 2009. PMID: 19535620 Free PMC article.
-
Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.Eur J Immunol. 2009 Jan;39(1):56-66. doi: 10.1002/eji.200738098. Eur J Immunol. 2009. PMID: 19065646 Free PMC article.
-
Phase I dendritic cell p53 peptide vaccine for head and neck cancer.Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583792 Free PMC article. Clinical Trial.
-
Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.Oncoimmunology. 2015 Aug 31;5(2):e1082028. doi: 10.1080/2162402X.2015.1082028. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057464 Free PMC article.
-
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.J Clin Oncol. 2010 Oct 1;28(28):4390-9. doi: 10.1200/JCO.2009.27.6360. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697078 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous